Source: Healio News
The FDA cleared an investigational new drug application for P-BCMA-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma.
P-BCMA-ALLO1 (Poseida Therapeutics) is an allogeneic, gene-edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.
The therapy comprises a high percentage of healthy donor stem cell memory T cells that are genetically edited to reduce alloreactivity and graft-versus-host disease by knocking out the T-cell receptor and major histocompatibility complex-1.
The